With IPO, have the capital and resources for clinical studies: Bicara CEO

​​As per Reuters, shares of Bicara Therapeutics surged nearly 46% in their debut on September 13, giving the TPG-backed cancer therapy developer a market value of $1.29 billion. Its shares opened at $26.25, compared with the offer price of $18, the news agency said. Bicara raised $315 million by selling 17.5 million shares in its initial public offering, after increasing the size of its offer twice, it said.